Dual Inhibitory Action on Aldosterone by Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition

Overview

Journal Hypertens Res

Specialty Cardiology & Vascular Diseases

Date 2016 Jun 24

PMID 27334065

Authors

Kouichi Tamura

Ryu Kobayashi

Sona Haku

Kengo Azushima

Hiromichi Wakui

Affiliations

Soon will be listed here.

References

Hubers S, Brown N . Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation. 2016; 133(11):1115-24. PMC: 4800749. DOI: 10.1161/CIRCULATIONAHA.115.018622. View

Cuspidi C, Tadic M, Sala C . Aldosterone and abnormal left ventricular geometry in chronic kidney disease. Hypertens Res. 2015; 38(5):314-6. DOI: 10.1038/hr.2015.34. View

Kario K, Sun N, Chiang F, Supasyndh O, Baek S, Inubushi-Molessa A . Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014; 63(4):698-705. DOI: 10.1161/HYPERTENSIONAHA.113.02002. View

Go A, Bauman M, Coleman King S, Fonarow G, Lawrence W, Williams K . An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2013; 63(4):878-85. PMC: 10280688. DOI: 10.1161/HYP.0000000000000003. View

Ito S, Satoh M, Tamaki Y, Gotou H, Charney A, Okino N . Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Hypertens Res. 2015; 38(4):269-75. PMC: 4396400. DOI: 10.1038/hr.2015.1. View

Mule G, Nardi E, Guarino L, Cacciatore V, Geraci G, Calcaterra I . Plasma aldosterone and its relationship with left ventricular mass in hypertensive patients with early-stage chronic kidney disease. Hypertens Res. 2015; 38(4):276-83. DOI: 10.1038/hr.2014.171. View

Mangiafico S, Costello-Boerrigter L, Andersen I, Cataliotti A, Burnett Jr J . Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J. 2012; 34(12):886-893c. PMC: 3604644. DOI: 10.1093/eurheartj/ehs262. View

Ruilope L, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz M . Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010; 375(9722):1255-66. DOI: 10.1016/S0140-6736(09)61966-8. View

McMurray J, Packer M, Desai A, Gong J, Lefkowitz M, Rizkala A . Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11):993-1004. DOI: 10.1056/NEJMoa1409077. View

10.

Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M . The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res. 2014; 37(4):253-390. DOI: 10.1038/hr.2014.20. View

11.

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M . 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31(7):1281-357. DOI: 10.1097/01.hjh.0000431740.32696.cc. View

12.

Monge M, Lorthioir A, Bobrie G, Azizi M . New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension. J Renin Angiotensin Aldosterone Syst. 2013; 14(4):285-9. DOI: 10.1177/1470320313513408. View

13.

Yancy C, Jessup M, Bozkurt B, Butler J, Casey Jr D, Drazner M . 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128(16):e240-327. DOI: 10.1161/CIR.0b013e31829e8776. View

14.

James P, Oparil S, Carter B, Cushman W, Dennison-Himmelfarb C, Handler J . 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2013; 311(5):507-20. DOI: 10.1001/jama.2013.284427. View

15.

Mozaffarian D, Benjamin E, Go A, Arnett D, Blaha M, Cushman M . Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2014; 131(4):e29-322. DOI: 10.1161/CIR.0000000000000152. View

16.

Weber M, Schiffrin E, White W, Mann S, Lindholm L, Kenerson J . Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2013; 16(1):14-26. PMC: 8031779. DOI: 10.1111/jch.12237. View

17.

Miura S, Suematsu Y, Matsuo Y, Tomita S, Nakayama A, Goto M . The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line. Hypertens Res. 2016; 39(11):758-763. DOI: 10.1038/hr.2016.72. View